Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness

Table 4 Summary of cytokine profile changes in Zucker Obese (ZO) rats treated with sacubitril/valsartan (ZOSV), valsartan (ZOV), and hydralazine (ZOH) when compared to control rats (ZOC)

Molecule	Gene	ZOSV /ZOC		ZOV/ZOC		ZOH/ZOC
Molecule	Gene	log₂FC	P-value	log₂FC	P-value	log₂FC	P-value
Neuropilin-1	Nrp1	− 0.266	0.001	− 0.398	0.005	− 0.173	0.052
Notch1	Notch1	− 0.768	0.003	− 1.108	0.002	− 0.976	0.002
PDGF-AA	Pdgfa	1.054	0.041
L-Selectin	Sell	0.800	0.044
IFNg	Ifng	0.550	0.020
IL-4	Il4	0.386	2.61E-05
JAM-A	F11r	-− 0.271	0.021	− 0.317	0.010
RANTES	Ccl5			− 0.436	0.014
Flt-3L	Flt3l			− 0.464	0.047
IL-17F	Il17f					− 0.668	0.037
Galectin-3	Lgals3					− 0.572	0.044

Notch Notch receptor 1, IFN Interferon, JAM-A Junctional Adhesion Molecule A, Flt-3L FMS related Receptor Tyrosine Kinase 3 Ligand
Molecules on the cytokine array that showed at least log₂ fold-change (log₂FC) of 1.2 and with a p-value ≤ 0.05 are shown. Statistical significance between the indicated groups determined by unpaired two-tailed t-tests. Gene symbols corresponding to each cytokine are shown. Sample size: N = 4/group

ISSN: 1475-2840